Search tips
Search criteria 


Logo of autoimmdisJournal's HomeManuscript SubmissionAims and ScopeAuthor GuidelinesEditorial BoardHome
Autoimmune Dis. 2012; 2012: 725249.
Published online Aug 5, 2012. doi:  10.1155/2012/725249
PMCID: PMC3419396
Osteonecrosis in Systemic Lupus Erythematosus: An Early, Frequent, and Not Always Symptomatic Complication
Paola Caramaschi,* Domenico Biasi, Ilaria Dal Forno, and Silvano Adami
Rheumatology Unit, Department of Medicine, University of Verona, 37134 Verona, Italy
*Paola Caramaschi: paola.caramaschi/at/
Academic Editor: Hiroshi Okamoto
Received May 16, 2012; Accepted June 16, 2012.
Osteonecrosis may complicate the course of systemic lupus erythematosus and may contemporaneously affect multiple joints. The major risk factor associated with the development of osteonecrosis is the use of glucocorticoid at high doses. Recent studies using serial MRI, which represents the “gold standard” for the early detection of osteonecrosis, yielded some interesting findings about the natural history of this clinical entity. Osteonecrosis in the majority of the cases is asymptomatic and occurs early in the course of the disease. Its later occurrence is associated with lupus flare that requires the increase of corticosteroid dose. The optimal treatment of osteonecrosis is controversial. In case of silent osteonecrosis involving a small area conservative strategy is usually adequate. When lesions are symptomatic surgical treatment as core decompression or free vascularized fibular grafting is required; extracorporeal shockwave treatment may represent an alternative therapeutic approach. When the lesion has a medium-large dimension or involves a weight-bearing area bone collapse is a common complication requiring total joint replacement. Coadministration of bisphosphonate or warfarin with high doses of corticosteroid might be a promising preventive strategy of osteonecrosis.
Articles from Autoimmune Diseases are provided here courtesy of
Hindawi Publishing Corporation